Direct-to-Consumer Genetic Testing
Summary of a Workshop
Seiten
2010
National Academies Press (Verlag)
978-0-309-38358-5 (ISBN)
National Academies Press (Verlag)
978-0-309-38358-5 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Today, scores of companies, primarily in the United States and Europe, are offering whole genome scanning services directly to the public. The proliferation of these companies and the services they offer demonstrate a public appetite for this information and where the future of genetics may be headed; they also demonstrate the need for serious discussion about the regulatory environment, patient privacy, and other policy implications of direct-to-consumer (DTC) genetic testing.
Rapid advances in genetic research already have begun to transform clinical practice and our understanding of disease progression. Existing research has revealed a genetic basis or component for numerous diseases, including Parkinson's disease, Alzheimer's disease, diabetes, heart disease, and several forms of cancer. The availability of the human genome sequence and the HapMap, plummeting costs of high-throughput screening, and increasingly sophisticated computational analyses have led to an explosion of discoveries of linkages between patterns of genetic variation and disease susceptibility. While this research is by no means a straight path toward better public health, improved knowledge of the genetic linkages has the potential to change fundamentally the way health professionals and public health practitioners approach the prevention and treatment of disease. Realizing this potential will require greater sophistication in the interpretation of genetic tests, new training for physicians and other diagnosticians, and new approaches to communicating findings to the public. As this rapidly growing field matures, all of these questions require attention from a variety of perspectives.
To discuss some of the foregoing issues, several units of the National Academies held a workshop on August 31 and September 1, 2009, to bring together a still-developing community of professionals from a variety of relevant disciplines, to educate the public and policy-makers about this emerging field, and to identify issues for future study. The meeting featured several invited presentations and discussions on the many technical, legal, policy, and ethical questions that such DTC testing raises, including: (1) overview of the current state of knowledge and the future research trajectory; (2) shared genes and emerging issues in privacy; (3) the regulatory framework; and (4) education of the public and the medical community.
Table of Contents
Front Matter
Introduction
Scientific Foundations for Direct-to-Consumer Genetic Testing
Personal and Social Issues
Research and Medical Issues
Impact on Health Care and Public Health
Current Legislative and Regulatory Framework in the United States
Areas for Further Study
Appendixes
Appendix A: Glossary Of Terms And Acronyms
Appendix B: Regulation of Direct-to-Consumer Genetic Testing Outside the United States
Appendix C: Currently Available Direct-to-Consumer Genetic Tests
Appendix D: Representative Direct-to-Consumer Genetic Testing Companies
Appendix E: Planning Group Biographies
Appendix F: Workshop Agenda
Appendix G: Workshop Participants
Appendix H: Membership of Oversight Boards and Committees
Rapid advances in genetic research already have begun to transform clinical practice and our understanding of disease progression. Existing research has revealed a genetic basis or component for numerous diseases, including Parkinson's disease, Alzheimer's disease, diabetes, heart disease, and several forms of cancer. The availability of the human genome sequence and the HapMap, plummeting costs of high-throughput screening, and increasingly sophisticated computational analyses have led to an explosion of discoveries of linkages between patterns of genetic variation and disease susceptibility. While this research is by no means a straight path toward better public health, improved knowledge of the genetic linkages has the potential to change fundamentally the way health professionals and public health practitioners approach the prevention and treatment of disease. Realizing this potential will require greater sophistication in the interpretation of genetic tests, new training for physicians and other diagnosticians, and new approaches to communicating findings to the public. As this rapidly growing field matures, all of these questions require attention from a variety of perspectives.
To discuss some of the foregoing issues, several units of the National Academies held a workshop on August 31 and September 1, 2009, to bring together a still-developing community of professionals from a variety of relevant disciplines, to educate the public and policy-makers about this emerging field, and to identify issues for future study. The meeting featured several invited presentations and discussions on the many technical, legal, policy, and ethical questions that such DTC testing raises, including: (1) overview of the current state of knowledge and the future research trajectory; (2) shared genes and emerging issues in privacy; (3) the regulatory framework; and (4) education of the public and the medical community.
Table of Contents
Front Matter
Introduction
Scientific Foundations for Direct-to-Consumer Genetic Testing
Personal and Social Issues
Research and Medical Issues
Impact on Health Care and Public Health
Current Legislative and Regulatory Framework in the United States
Areas for Further Study
Appendixes
Appendix A: Glossary Of Terms And Acronyms
Appendix B: Regulation of Direct-to-Consumer Genetic Testing Outside the United States
Appendix C: Currently Available Direct-to-Consumer Genetic Tests
Appendix D: Representative Direct-to-Consumer Genetic Testing Companies
Appendix E: Planning Group Biographies
Appendix F: Workshop Agenda
Appendix G: Workshop Participants
Appendix H: Membership of Oversight Boards and Committees
1 Front Matter; 2 Introduction; 3 Scientific Foundations for Direct-to-Consumer Genetic Testing; 4 Personal and Social Issues; 5 Research and Medical Issues; 6 Impact on Health Care and Public Health; 7 Current Legislative and Regulatory Framework in the United States; 8 Areas for Further Study; 9 Appendixes; 10 Appendix A: Glossary Of Terms And Acronyms; 11 Appendix B: Regulation of Direct-to-Consumer Genetic Testing Outside the United States; 12 Appendix C: Currently Available Direct-to-Consumer Genetic Tests; 13 Appendix D: Representative Direct-to-Consumer Genetic Testing Companies; 14 Appendix E: Planning Group Biographies; 15 Appendix F: Workshop Agenda; 16 Appendix G: Workshop Participants; 17 Appendix H: Membership of Oversight Boards and Committees
| Verlagsort | Washington |
|---|---|
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Themenwelt | Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| ISBN-10 | 0-309-38358-7 / 0309383587 |
| ISBN-13 | 978-0-309-38358-5 / 9780309383585 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Eine sehr persönliche Geschichte | Der New York Times-Bestseller
Buch | Softcover (2023)
Ullstein Taschenbuch Verlag
CHF 30,75
Die revolutionäre Medizin von morgen (Lifespan)
Buch | Softcover (2020)
DuMont Buchverlag
CHF 22,40
Buch | Softcover (2022)
John Wiley & Sons Inc (Verlag)
CHF 169,95
